The PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) platform is designed to improve intervention efficacy of hard-to-treat cancers, such as lung and pancreatic, while remaining effective against evolving tumor clones with increasingly drug resistance and immunosuppression. The technology will provide enhanced engagement capabilities against modern threats, with improved prediction power and interoperability with existing laboratory instruments.

The launch of PGA will not only benefit those patient non-responders but also improve responsiveness to other treatment options at a time when the widespread use of combination therapy is making cancer therapy increasingly complex. PGA is designed to provide additional options for patients unresponsive to precision therapy, creating a never-before opportunity adapted to personalized medicine.

The OncoMRD (Monitoring Residual Disease) technology will be specifically configured for monitoring “residual tumor activity” beyond mutation detection. It will feature a cancer type-specific gene panel armed with key biomarkers to establish a patient-unique gene expression signature for MRD detection, tracking and quantification. The detection capability will enable continuous tumor monitoring, quantifying and tracking tumor activity before they pose a threat to the intervention. Given the increasing frequency of drug resistance, disease progression and relapse, this blood-based responsive system is intended to enhance therapeutic efficacy.

OncoMRD will provide additional surveillance along disease progression. By offering a rapid and effective response to residual tumor activity, OncoMRD will complement DNA mutation-detecting MRD systems, which have traditionally been limited to tumor cells and left out relevant tumor microenvironment signals. The OncoMRD approach will allow clinicians to operate with greater confidence while reducing turnaround time and cost.

The technical breakthroughs of PGA and OncoMRD represent a progressive expansion of OncoDxRx’s precision theranostics and counter-cancer capabilities. They will complement the standard-of-care biomarker tests and complete the coverage of entire patient population. With this innovation effort, OncoDxRx aims to develop a coordinated and adaptive decision-supporting system to benefit patients and improve outcomes. The launch of PGA and OncoMRD will support a more resilient and dynamic pipeline posture, enabling OncoDxRx to better address evolving cancer challenges.